Replies to post #5342 on Halozyme Therapeutics Inc (HALO)

[maumar]

Thanks. I skimmed through the conference call transcript.

"So let's now move to slide eight. The biggest standout in this quarter continues to be the strength of our Immunology business. If you recall, this business, which has obvious synergies with our hereditary angioedema business, was one of the core reasons we decided to acquire Baxalta.

....

Additionally, we're seeing more patients choose home administration, where our two subcutaneously delivered immunoglobulin products, that is HYQVIA and CUVITRU are taking share and grew approximately 75% in the quarter compared to the third quarter of last year.

.....

and what has impressed me the most, particularly the U.S., but now also starting ex-U.S. is incredibly high growth of the subcutaneous segment, 75% growth. HYQVIA and CUVITRU are doing extremely well.

....

we also think the trend in the marketplace is more out-of-hospital, at-home treatment. So we're extremely positive about that."